Stein Eye Institute, David Geffen of Medicine at UCLA, Los Angeles, California, USA.
Southern California Desert Retina Consultants, Palm Desert, California, USA.
Ocul Immunol Inflamm. 2022 Jul;30(5):1211-1213. doi: 10.1080/09273948.2021.1872649. Epub 2021 Apr 1.
The immune checkpoint inhibitors (ICPIs) comprise a class of oncologic immunotherapies. The most recent US Food and Drug Administration-approved ICPI is cemiplimab (Libtayo®). Cemiplimab, like the other ICPIs, blocks checkpoint receptors in order to disinhibit T-cells so that they may detect and eliminate tumor cells. Consequently, treatment with ICPIs is associated with immune-related adverse events including uveitis.
Case report.
A 63-year-old man with a history of metastatic squamous cell carcinoma developed blurry vision 3 months after starting treatment with cemiplimab. The patient was found to have posterior uveitis with retinal vasculitis that was successfully controlled with discontinuation of the medication as well as treatment with local and systemic steroids.
Similar to other ICPIs, uveitis may be associated with cemiplimab. In the setting of posterior uveitis, treatment may require cessation of cemiplimab and intensive steroid treatment.
免疫检查点抑制剂（ICPIs）是一类肿瘤免疫疗法。最近获得美国食品和药物管理局批准的 ICPI 是西米普利单抗（Libtayo®）。西米普利单抗与其他 ICPIs 一样，通过阻断检查点受体来抑制 T 细胞，使其能够检测和消除肿瘤细胞。因此，使用 ICPIs 与免疫相关的不良反应有关，包括葡萄膜炎。
病例报告。
一名 63 岁男性患有转移性鳞状细胞癌，在开始使用西米普利单抗治疗 3 个月后出现视力模糊。发现患者患有后葡萄膜炎伴视网膜血管炎，通过停用药物以及局部和全身类固醇治疗成功控制了病情。
与其他 ICPIs 类似，葡萄膜炎可能与西米普利单抗有关。在后葡萄膜炎的情况下，可能需要停止西米普利单抗治疗并进行强化类固醇治疗。
